| Year |
Citation |
Score |
| 2018 |
Kamal M, Tarcic G, Dureau S, Edelheit O, Barbash Z, Lecerf C, Morel C, Miron B, Callens C, Servant N, Bieche I, Vidne M, Le Tourneau C. Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome. Molecular Oncology. PMID 29464843 DOI: 10.1002/1878-0261.12180 |
0.33 |
|
| 2017 |
Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouse M, Dvir A, Soussan-Gutman L, Barlesi F, Tarcic G, Edelheit O, Gandara D, Elkabetz Y. Sub-Clonal Therapy by two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-mutated Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28286242 DOI: 10.1016/J.Jtho.2017.02.023 |
0.331 |
|
| 2017 |
Loree JM, Miron B, Holla V, Overman MJ, Pereira AAL, Lam M, Morris VK, Raghav KPS, Routbort M, Shaw KR, Burck N, Sharivkin R, Edelheit O, Meric-Bernstam F, Vidne M, et al. Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations. Journal of Clinical Oncology. 35: 3589-3589. DOI: 10.1200/Jco.2017.35.15_Suppl.3589 |
0.318 |
|
| 2017 |
Miron B, Tarcic G, Edelheit O, Burck N, Vidne M, Roisman L, Peled N. Abstract LB-041: Novel platform to profile variants of uncertain significant (VUS) with preliminary retrospective clinical validation in non-small cell lung cancer (NSCLC) Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-041 |
0.363 |
|
| 2017 |
Tarcic G, Le Tourneau C, Kamal M, Edelheit O, Barbash Z, Vidne M, Dureau S, Miron B, Callens C, Servant N, Bieche I. Retrospective analysis of a SHIVA01 trial cohort using functional mutational analysis successfully predicted treatment outcome Annals of Oncology. 28: v450-v451. DOI: 10.1093/Annonc/Mdx378.007 |
0.341 |
|
| 2016 |
Tarcic G, Peled N, Barbash Z, Edelheit O, Vidne M, Kramer MR. Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025): Interim results. Journal of Clinical Oncology. 34: e20066-e20066. DOI: 10.1200/Jco.2016.34.15_Suppl.E20066 |
0.327 |
|
| 2016 |
Sullivan RJ, Barbash Z, Edelheit O, Vidne M, Sosman JA, Flaherty K, Davies MA, Johnson DB, Tarcic G. Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram). Journal of Clinical Oncology. 34: 9537-9537. DOI: 10.1200/Jco.2016.34.15_Suppl.9537 |
0.434 |
|
| 2016 |
Tarcic G, Simon DA, Jacobstein M, Lanman RB, Vidne M, Barbash Z, Edelheit O, Talasaz A. Functional characterization of VUS mutations found in patients' cell-free circulating tumor DNA (ctDNA) using Precision Cancer Analysis System (PCAS). Journal of Clinical Oncology. 34: 11576-11576. DOI: 10.1200/Jco.2016.34.15_Suppl.11576 |
0.367 |
|
| 2016 |
Miron B, Peled N, Barbash Z, Edelheit O, Vidne M, Sharivkin R, Tarcic G. Functional characterization of mutations and their interaction using the novel functional annotation for cancer treatment (FACT) platform Annals of Oncology. 27: vi404. DOI: 10.1093/Annonc/Mdw380.10 |
0.364 |
|
| 2016 |
Tarcic G, Kamal M, Edelheit O, Barbash Z, Vidne M, Miron B, Callens C, Servant N, Bièche I, Le Tourneau C. Functional mutational analysis to assess the oncogenic activity of variant of uncertain significance (VUS) detected in patients included in the SHIVA trial European Journal of Cancer. 69: S6-S7. DOI: 10.1016/S0959-8049(16)32618-1 |
0.392 |
|
| 2014 |
Edelheit O, Ben-Shahar R, Dascal N, Hanukoglu A, Hanukoglu I. Conserved charged residues at the surface and interface of epithelial sodium channel subunits--roles in cell surface expression and the sodium self-inhibition response. The Febs Journal. 281: 2097-111. PMID 24571549 DOI: 10.1111/Febs.12765 |
0.672 |
|
| 2012 |
Enuka Y, Hanukoglu I, Edelheit O, Vaknine H, Hanukoglu A. Epithelial sodium channels (ENaC) are uniformly distributed on motile cilia in the oviduct and the respiratory airways. Histochemistry and Cell Biology. 137: 339-53. PMID 22207244 DOI: 10.1007/S00418-011-0904-1 |
0.575 |
|
| 2011 |
Edelheit O, Hanukoglu I, Dascal N, Hanukoglu A. Identification of the roles of conserved charged residues in the extracellular domain of an epithelial sodium channel (ENaC) subunit by alanine mutagenesis. American Journal of Physiology. Renal Physiology. 300: F887-97. PMID 21209000 DOI: 10.1152/Ajprenal.00648.2010 |
0.681 |
|
| 2010 |
Edelheit O, Hanukoglu I, Shriki Y, Tfilin M, Dascal N, Gillis D, Hanukoglu A. Truncated beta epithelial sodium channel (ENaC) subunits responsible for multi-system pseudohypoaldosteronism support partial activity of ENaC. The Journal of Steroid Biochemistry and Molecular Biology. 119: 84-8. PMID 20064610 DOI: 10.1016/J.Jsbmb.2010.01.002 |
0.66 |
|
| 2009 |
Edelheit O, Hanukoglu A, Hanukoglu I. Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies. Bmc Biotechnology. 9: 61. PMID 19566935 DOI: 10.1186/1472-6750-9-61 |
0.601 |
|
| 2008 |
Hanukoglu A, Edelheit O, Shriki Y, Gizewska M, Dascal N, Hanukoglu I. Renin-aldosterone response, urinary Na/K ratio and growth in pseudohypoaldosteronism patients with mutations in epithelial sodium channel (ENaC) subunit genes. The Journal of Steroid Biochemistry and Molecular Biology. 111: 268-74. PMID 18634878 DOI: 10.1016/J.Jsbmb.2008.06.013 |
0.655 |
|
| 2005 |
Edelheit O, Hanukoglu I, Gizewska M, Kandemir N, Tenenbaum-Rakover Y, Yurdakök M, Zajaczek S, Hanukoglu A. Novel mutations in epithelial sodium channel (ENaC) subunit genes and phenotypic expression of multisystem pseudohypoaldosteronism. Clinical Endocrinology. 62: 547-53. PMID 15853823 DOI: 10.1111/J.1365-2265.2005.02255.X |
0.653 |
|
| Show low-probability matches. |